Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

AFMD

Affimed N.V.

May 29 • 04:00PM ET

4.02

Dollar change -0.05
Percentage change -1.23	%

Healthcare • Biotechnology • Germany • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: FESM GWX SPDW

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.07	Insider Own	14.49%	Shs Outstand	15.00M	Perf Week	-21.94%
Market Cap	61.22M	Forward P/E	-	EPS next Y	-4.12	Insider Trans	0.00%	Shs Float	13.02M	Perf Month	-26.78%
Income	-114.53M	PEG	-	EPS next Q	-1.66	Inst Own	24.40%	Short Float	1.77%	Perf Quarter	-31.86%
Sales	8.93M	P/S	6.86	EPS this Y	28.07%	Inst Trans	-24.80%	Short Ratio	2.41	Perf Half Y	-10.67%
Book/sh	4.26	P/B	0.94	EPS next Y	25.41%	ROA	-71.29%	Short Interest	0.23M	Perf Year	-51.43%
Cash/sh	5.23	P/C	0.77	EPS next 5Y	-	ROE	-100.88%	52W Range	2.23 - 9.10	Perf YTD	-35.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-82.40%	ROI	-146.47%	52W High	-55.82%	Beta	2.01
Dividend TTM	-	Quick Ratio	3.23	Sales past 5Y	-4.04%	Gross Margin	-	52W Low	79.87%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	3.25	EPS Y/Y TTM	-225.39%	Oper. Margin	-1347.97%	RSI (14)	24.31	Volatility	8.91% 6.85%
Employees	78	Debt/Eq	0.33	Sales Y/Y TTM	-79.29%	Profit Margin	-1282.50%	Recom	1.33	Target Price	16.83
Option/Short	Yes / Yes	LT Debt/Eq	0.22	EPS Q/Q	-520.96%	Payout	-	Rel Volume	4.23	Prev Close	4.07
Sales Surprise	-72.33%	EPS Surprise	9.30%	Sales Q/Q	-96.10%	Earnings	Mar 28 BMO	Avg Volume	95.68K	Price	4.02
SMA20	-21.52%	SMA50	-24.97%	SMA200	-20.50%	Trades		Volume	404,342	Change	-1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-22	Initiated	H.C. Wainwright	Buy	$6
Oct-10-22	Downgrade	Stifel	Buy → Hold	$9 → $2
Aug-18-22	Resumed	Wells Fargo	Overweight
Mar-31-22	Initiated	Piper Sandler	Overweight	$7
Feb-23-22	Initiated	Cantor Fitzgerald	Overweight	$12
Oct-21-21	Initiated	Truist	Buy	$10
Sep-30-21	Initiated	Stifel	Buy	$12
Mar-31-21	Initiated	Credit Suisse	Outperform	$15
Mar-28-19	Initiated	SVB Leerink	Outperform
Aug-28-18	Upgrade	Jefferies	Hold → Buy
Jul-14-17	Initiated	SunTrust	Buy	$7
Aug-12-16	Downgrade	Leerink Partners	Outperform → Mkt Perform
May-19-16	Downgrade	Leerink Partners	Outperform → Mkt Perform
Dec-10-15	Initiated	Laidlaw	Buy	$15
Dec-04-15	Initiated	Wells Fargo	Outperform
Sep-09-15	Initiated	Jefferies	Hold
Aug-06-15	Reiterated	Oppenheimer	Outperform	$14 → $19
Jun-22-15	Reiterated	Jefferies	Buy	$12 → $16

Show Previous Ratings

May-29-24 06:30AM	Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer (GlobeNewswire)
May-28-24 06:30AM	Affimed Announces Annual General Meeting of Shareholders (GlobeNewswire)
06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-23-24 05:05PM	Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024 (GlobeNewswire)
May-17-24 03:55PM	Small-Cap Sensations: 3 Stocks Under $10 With 10X Potential (InvestorPlace)
10:05AM	Loading…
May-14-24 10:05AM	Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress (GlobeNewswire)
Apr-24-24 09:55AM	Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade (Zacks) -8.79%
04:05AM	Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology (GlobeNewswire)
Apr-17-24 09:55AM	Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Apr-04-24 09:55AM	Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect? (Zacks)
Apr-01-24 11:38AM	Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript (Insider Monkey) +19.81%
Mar-28-24 06:30AM	Affimed Reports 2023 Financial Results and Operational Progress (GlobeNewswire)
Mar-21-24 06:30AM	Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024 (GlobeNewswire)
Mar-14-24 12:00PM	Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know (Zacks) -8.14%
Mar-06-24 03:36PM	7 of the Best Speculative Stocks You Can Snag for Less Than $1 (InvestorPlace) -14.80%
06:30AM	Loading…
06:30AM	Affimed Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Jan-08-24 04:05PM	Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer (GlobeNewswire) +7.36%
08:00AM	Affimed Announces Leadership Change and Organizational Restructuring (GlobeNewswire)
Jan-03-24 06:30AM	Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck (GlobeNewswire) -5.95%
Dec-19-23 09:08AM	3 Penny Stocks That Are Too Compelling to Ignore (InvestorPlace)
Dec-11-23 06:02AM	Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients (GlobeNewswire) -12.26%
06:00AM	Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs) (GlobeNewswire)
03:18AM	Premarket movers: Macy's, Cigna climb; Sea Ltd ADRs fall (Investing.com)
Dec-04-23 06:30AM	Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24 (GlobeNewswire)
Nov-20-23 08:51AM	Affimed N.V. (NASDAQ:AFMD) Q3 2023 Earnings Call Transcript (Insider Monkey) +17.28%
Nov-14-23 06:38AM	Affimed N.V.: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress (GlobeNewswire)
Nov-09-23 06:30AM	Affimed Announces Acimtamig as International Nonproprietary Name for AFM13 (GlobeNewswire) -7.23%
Nov-07-23 06:30AM	Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023 (GlobeNewswire)
Nov-03-23 12:05PM	Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire)
09:05AM	Loading…
Nov-02-23 09:05AM	Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting (GlobeNewswire)
Nov-01-23 06:30AM	Affimed to Participate in Upcoming Investor Conferences (GlobeNewswire) -10.03%
Oct-31-23 07:12PM	5 Best German Stocks To Buy Now (Insider Monkey) +18.65%
Oct-25-23 09:35AM	Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround (Zacks)
Oct-04-23 06:30AM	Affimed Announces Listing Transfer to Nasdaq Capital Markets (GlobeNewswire)
Sep-27-23 09:05AM	Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire)
Sep-21-23 06:30AM	Affimed to Present at the Cantor Global Healthcare Conference 2023 (GlobeNewswire)
Sep-12-23 06:30AM	Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma (GlobeNewswire)
Sep-07-23 06:30AM	Affimed to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-23-23 12:11PM	Is Affimed NV Set to Underperform? Analyzing the Factors Limiting Growth (GuruFocus.com) +11.67%
06:00AM	Surprise! These 3 Penny Stocks Have Wall Streets Seal of Approval. (InvestorPlace)
Aug-22-23 05:00AM	Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability (GlobeNewswire)
Aug-10-23 07:50AM	Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
06:42AM	Affimed N.V.: Q2 Earnings Snapshot (AP Finance)
06:30AM	Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress (GlobeNewswire)
Aug-09-23 06:02AM	Some Analysts Just Cut Their Affimed N.V. (NASDAQ:AFMD) Estimates (Simply Wall St.)
Aug-04-23 04:51PM	3 Cheap Stocks to Buy Under $1 in August 2023 (InvestorPlace)
Aug-03-23 06:30AM	Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023 (GlobeNewswire)
Jul-31-23 05:05PM	Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotechs SNK01 NK Cells (GlobeNewswire)
Jun-22-23 06:30AM	Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board (GlobeNewswire)
Jun-09-23 05:59PM	Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML) (GlobeNewswire)
Jun-06-23 07:51AM	Affimed (NASDAQ:AFMD) shareholders have endured a 78% loss from investing in the stock three years ago (Simply Wall St.)
Jun-03-23 09:00AM	Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan (GlobeNewswire)
May-30-23 06:30AM	Affimed to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-25-23 05:00PM	Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology (GlobeNewswire) -10.07%
May-23-23 07:45AM	Affimed N.V. (AFMD) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -9.69%
06:37AM	Affimed N.V.: Q1 Earnings Snapshot (AP Finance)
06:30AM	Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress (GlobeNewswire)
06:15AM	Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy (GlobeNewswire)
May-22-23 06:30AM	Affimed Announces Annual General Meeting of Shareholders (GlobeNewswire)
May-16-23 06:30AM	Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023 (GlobeNewswire)
May-11-23 10:05AM	Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association (GlobeNewswire)
May-05-23 06:14AM	Affimed N.V.'s (NASDAQ:AFMD) Price Is Right But Growth Is Lacking (Simply Wall St.)
Apr-26-23 10:00AM	Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO) (GlobeNewswire) +7.66%
Apr-17-23 04:05PM	Affimed Shares Preclinical Data on AFM13s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting (GlobeNewswire) +7.78%
Apr-16-23 03:00PM	Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Apr-06-23 04:05PM	Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
Mar-30-23 08:19AM	Affimed N.V. (NASDAQ:AFMD) is a favorite amongst institutional investors who own 52% (Simply Wall St.)
Mar-29-23 06:30AM	Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia (GlobeNewswire) +8.79%
Mar-27-23 06:21AM	Affimed N.V. (NASDAQ:AFMD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-23-23 07:45AM	Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -6.39%
06:30AM	Affimed Reports 2022 Financial Results and Operational Progress (GlobeNewswire)
Mar-16-23 06:30AM	Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023 (GlobeNewswire)
Mar-14-23 04:30PM	Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research (GlobeNewswire)
Mar-09-23 05:00AM	AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery (GlobeNewswire)
Feb-22-23 06:30AM	Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Feb-21-23 05:00AM	AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target (GlobeNewswire)
Feb-08-23 06:30AM	Affimed to Present at the SVB Securities 2023 Global Biopharma Conference (GlobeNewswire) -6.78%
Jan-09-23 06:30AM	Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13 (GlobeNewswire) -10.42%
Dec-28-22 06:41AM	Investors in Affimed (NASDAQ:AFMD) have unfortunately lost 80% over the last year (Simply Wall St.)
Dec-22-22 06:30AM	Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire)
Dec-16-22 09:35AM	Here's Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 Weeks (Zacks)
Dec-12-22 01:01PM	Analyst Says Affimed's 'Innate Cell Engagers Like No Others,' Sees Mammoth Upside (Benzinga) -33.33%
10:00AM	Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting (GlobeNewswire)
05:50AM	Citing Lack Of Durability, Affimed Scraps AFM13 Monotherapy Plans For NK Cell Combo (Benzinga)
Dec-10-22 03:00PM	Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (GlobeNewswire)
02:20PM	Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting (GlobeNewswire)
Dec-01-22 04:05PM	Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting (GlobeNewswire)
Nov-17-22 04:01PM	Why Shares of Affimed Fell Thursday (Motley Fool) -14.29%
05:17AM	Affimed Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-15-22 07:45AM	Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +11.27%
06:30AM	Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress (GlobeNewswire)
Nov-07-22 08:05AM	Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting (GlobeNewswire) +22.56%
Nov-04-22 06:30AM	Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022 (GlobeNewswire) +5.41%
Nov-03-22 09:15AM	Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101 (GlobeNewswire) +9.47%
09:05AM	Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting (GlobeNewswire)
Nov-02-22 10:01AM	Analysts Estimate Affimed N.V. (AFMD) to Report a Decline in Earnings: What to Look Out for (Zacks) -6.11%
Nov-01-22 06:30AM	Affimed to Present at the 2022 Jefferies London Healthcare Conference (GlobeNewswire)
Oct-31-22 07:20PM	7 Undervalued Biotech Stocks to Buy Before They Boom (InvestorPlace)
Oct-21-22 08:18AM	With 50% ownership, Affimed N.V. (NASDAQ:AFMD) has piqued the interest of institutional investors (Simply Wall St.) +9.21%

Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AFMD

Affimed N.V.

Upgrade your FINVIZ experience